Gwen Nichols

Data-informed optimization of CAR T-cell therapy long-term follow-up

Betsy Foss-Campbell, Nancy Myers, Rakesh Awasthi, Dylan Bechtle et autres

Following administration of chimeric antigen receptor (CAR) T-cell therapy, extensive long-term follow-up (LTFU) requirements and complex data collection processes have posed significant challenges for patients and providers. To reassess whether a 15-year LTFU period remains scientifically justified, we convened a multistakeholder working …

us, ca (code pays fourni par la source)

Fertility Outcomes Following CAR T-cell Therapy: Results from a Patient-Facing Survey

John A. Ligon, Nina Logan, Grace Li, Sara Silbert et autres

us (code pays fourni par la source)

ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco Bautista et autres

Abstract Background Despite improvements in the treatment of children with acute myeloid leukemia (AML) with modern multi-agent therapy, survival after relapse remains poor. Outcomes are particularly suboptimal for patients unable to receive anthracycline-based salvage therapies due to prior cardiac toxicity or maximal …

nl, fr, us, de, jp, it, es (code pays fourni par la source)

A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML

Margarita Maurer‐Granofszky, Flavia Battistutta, Boutheina Bouslama, Lisa Eidenschink Brodersen et autres

Abstract Background Assessment of measurable residual disease by multidimensional flow cytometry (MFC-MRD) is critical for early response evaluation and risk-adapted treatment of pediatric acute myeloid leukemia (pedAML) serving as a robust surrogate endpoint of response and outcome in clinical trials. To guarantee …

at, au, fr, us, de, it, se, nl, gb (code pays fourni par la source)

APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A- rearranged , NUP98- rearranged , or NPM1- mutant Acute Leukemias

Elisabeth Salzer, Janine Stutterheim, Branko Cuglievan, Blake Tomkinson et autres

Background and Significance: Aberrant expression of HOX family and MEIS1 genes, commonly found in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant acute leukemias, leads to arrested differentiation and leukemia development. HOX family genes are crucial regulators of normal hematopoiesis, and their expression is controlled by …

de, us, nl (code pays fourni par la source)

MA16.08 Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC

Daniel H. Sterman, C. Aggarwal, E.R. Alesi, F. Maldonado et autres

us (code pays fourni par la source)

Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank

Konstantin A. Krychtiuk, Tomas Andersson, Ulrike Bodesheim, Javed Butler et autres

us, se, de (code pays fourni par la source)

The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia

Valeria Ceolin, S Ishimaru, Seth E. Karol, Francisco Bautista et autres

The prognosis of children with acute myeloid leukemia (AML) has improved incrementally over the last few decades. However, at relapse, overall survival (OS) is approximately 40-50% and is even lower for patients with chemo-refractory disease. Effective and less toxic therapies are urgently …

nl, it, us, fr, jp, gb, de (code pays fourni par la source)

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh et autres

The Leukemia Lymphoma Society (LLS) Pediatric Acute Leukemia (PedAL) Initiative is a collaborative international effort that aims to improve the cure of children with relapsed/refractory (R/R) and other high-risk leukemias. Its comprehensive approach included preclinical and clinical research, standardization and improvement of …

de, us, it, nl (code pays fourni par la source)

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert B. Gerbing, Jim J. Wang et autres

Background: Outcomes for children with relapsed acute myeloid leukemia (AML) and subgroups with relapsed acute lymphoblastic leukemia (ALL) remain poor, and therapeutic options are limited. There is no standard of care for relapsed disease, and data collection after relapse is lacking. In …

us, nl, de (code pays fourni par la source)

Data from Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies

Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, Jun Xu et autres

Abstract The anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies were examined in a real-world setting. A next-generation sequencing (NGS)–based molecular assay was used to assess SARS-CoV-2–specific T-cell responses. After the second dose, 58% (166/284) of …

Supplementary Figure from Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies

Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, Jun Xu et autres

Supplementary Figure from Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies